Rishi R Doshi1, Jorge A Fortun2, Brian T Kim1, Sander R Dubovy1, Philip J Rosenfeld1. 1. Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida. 2. Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida. Electronic address: jfortun@med.miami.edu.
Abstract
PURPOSE: To present 3 cases of tamoxifen-induced foveal cavitation and review previous prospective and cross-sectional studies. DESIGN: Observational case series. METHODS: Retrospective analysis of patients presenting to a single institution with evidence of tamoxifen-induced maculopathy. RESULTS: Three patients presented with pseudocystic foveal cavitation similar in appearance to macular telangiectasia type 2 on spectral-domain optical coherence tomography (SD OCT) imaging. CONCLUSIONS: Tamoxifen maculopathy is characterized by cavitation in the central macula with or without typical cystoid macular edema. Pathogenesis involves toxicity to retinal Müller cells. It can occur with low daily and cumulative doses of the drug, and in the absence of subjective visual complaints or crystalline retinopathy. Prospective research with SD OCT imaging will be required to gain a more accurate estimate of the incidence of tamoxifen retinopathy.
PURPOSE: To present 3 cases of tamoxifen-induced foveal cavitation and review previous prospective and cross-sectional studies. DESIGN: Observational case series. METHODS: Retrospective analysis of patients presenting to a single institution with evidence of tamoxifen-induced maculopathy. RESULTS: Three patients presented with pseudocystic foveal cavitation similar in appearance to macular telangiectasia type 2 on spectral-domain optical coherence tomography (SD OCT) imaging. CONCLUSIONS:Tamoxifenmaculopathy is characterized by cavitation in the central macula with or without typical cystoid macular edema. Pathogenesis involves toxicity to retinal Müller cells. It can occur with low daily and cumulative doses of the drug, and in the absence of subjective visual complaints or crystalline retinopathy. Prospective research with SD OCT imaging will be required to gain a more accurate estimate of the incidence of tamoxifenretinopathy.
Authors: Kalev Nõupuu; Winston Lee; Jana Zernant; Stephen H Tsang; Rando Allikmets Journal: Invest Ophthalmol Vis Sci Date: 2014-10-09 Impact factor: 4.799
Authors: Nicole Koulisis; Stavros N Moysidis; Lisa C Olmos de Koo; Christy A Russell; Amir H Kashani Journal: Am J Ophthalmol Case Rep Date: 2016-05-18